Hostname: page-component-7c8c6479df-nwzlb Total loading time: 0 Render date: 2024-03-28T04:04:00.168Z Has data issue: false hasContentIssue false

Ximelagatran: A new type of oral anticoagulant

Published online by Cambridge University Press:  25 October 2005

Lisa Kwok
Affiliation:
Fairview Family Health Network
Dana Molckovsky
Affiliation:
AstraZeneca Canada Inc.
Michel Boucher
Affiliation:
Canadian Coordinating Office for Health Technology Assessment

Abstract

Objectives: This assessment sought to evaluate the comparative benefit and adverse effect profile of ximelagatran, as well as the clinical issues surrounding its potential use.

Methods: We performed a Dialog OneSearch across BIOSIS Previews, EMBASE, MEDLINE, PASCAL, and ToxFile to identify published literature. PubMed and The Cochrane Library were also searched. Gray literature was identified by searching a variety of Web sites of health technology assessment and related agencies and their associated databases. The manufacturer's Canadian office, AstraZeneca, was invited to submit information.

Results: Ximelagatran is the first oral agent from a new class of anticoagulants called direct thrombin inhibitors. Other oral anticoagulants require routine blood monitoring; ximelagatran does not. Ximelagatran has been evaluated in the areas of venous thromboembolism management, particularly after orthopedic surgery, and stroke prevention in patients with atrial fibrillation. Overall, ximelagatran's efficacy appears comparable to other anticoagulants in these clinical settings. Also, bleeding rates were generally similar between ximelagatran and comparators but, as for warfarin, bleeding risk increases with higher ximelagatran doses. In addition, there is no specific antidote to help manage ximelagatran-induced bleeding. Finally, significantly more patients exposed to long-term ximelagatran developed elevated liver enzymes more than three times the upper normal limit, compared with patients on comparator anticoagulants.

Conclusions: Given its apparent simplicity of use, ximelagatran carries the potential to replace, at least in part, anticoagulants currently used in the management of venous thromboembolism or for preventing stroke in atrial fibrillation patients. However, the safety of ximelagatran will not be fully known without further evaluation and surveillance for potential liver toxicity. There is also a need to evaluate its use in special populations such as patients with renal failure and patients using several concurrent medications.

Type
GENERAL ESSAYS
Copyright
© 2005 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

AstraZeneca receives action letter from FDA for Exanta® (ximelagatran) [news release]. London: AstraZeneca International; October 11, 2004. Available at: http://www.astrazeneca.com/pressrelease/3285.aspx. Accessed October 28, 2004.
Albers GW, Dalen JE, Laupacis A, et al. 2001 Antithrombotic therapy in atrial fibrillation. Chest. 119: 194S206S.Google Scholar
Albers GW, Diener HC, Frison L, et al. 2005 Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: A randomized trial. JAMA. 293: 690698.Google Scholar
Center for Drug Evaluation and Research, US Food and Drug Administration. 2004. Integrated executive summary of FDA review for NDA 21-686 Exanta (ximelagatran) [Clinical review]. Rockville (MD): The Center; 2004. Available at: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4069B1_03_FDA-Backgrounder-Execsummaryredacted.pdf. Accessed October 7
Colwell CW, Berkowitz SD, Davidson BL, et al. 2003 Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost. 1: 21192130.Google Scholar
Colwell CW, Berkowitz SD, Comp PC, et al. 2003. Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR): EXULT B. American Society of Hematology 45th Annual Meeting and Exposition; December 6–9, 2003; San Diego. Available at: http://www.hematology.org/meeting/abstracts.cfm. Accessed December 16
Donnan GA, Dewey HM, Chambers BR. 2004 Warfarin for atrial fibrillation: The end of an era? Lancet Neurol. 3: 305308.Google Scholar
Eriksson BI, Agnelli G, Cohen AT, et al. 2003 The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: The EXPRESS study. J Thromb Haemost. 1: 24902496.Google Scholar
Eriksson BI, Agnelli G, Cohen AT, et al. 2003 Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement: The METHRO III Study. Thromb Haemost. 89: 288296.Google Scholar
Executive Steering Committee on behalf of the SPORTIF III Investigators. 2003 Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial. Lancet. 362: 16911698.
Fiessinger JN, Huisman MV, Davidson BL, et al. 2005 Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: A randomized trial. JAMA. 293: 681689.Google Scholar
Francis CW, Berkowitz SD, Comp PC, et al. 2003 Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 349: 17031712.Google Scholar
Francis CW, Davidson BL, Berkowitz SD, et al. 2002 Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med. 137: 648655.Google Scholar
Fuster V, Rydén LE, Asinger RW, et al. 2001 ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol. 38: 12311266.Google Scholar
Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. 2004. Chest. 2001;119:132S-175S. Available at: http://www.chestjournal.org/cgi/reprint/119/1_suppl/132S.pdf. Accessed April 7
Granger CB, Miller JM, Bovill EG, et al. 1995 Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation. 91: 19291935.Google Scholar
Gustafsson D. 2003 Oral direct thrombin inhibitors in clinical development. J Intern Med. 254: 322334.Google Scholar
Heit JA. 2003 The potential role of direct thrombin inhibitors in the prevention and treatment of venous thromboembolism. Chest. 124: 40S48S.Google Scholar
Hirsh J, Dalen J, Anderson DR, et al. 2001 Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 119: 8S21S.Google Scholar
Hull RD, Pineo GF, Stein PD, et al. 2001 Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: A systematic review. Arch Intern Med. 161: 19521960.Google Scholar
Hyers TM. 2003 Management of venous thromboembolism: Past, present, and future. Arch Intern Med. 163: 759768.Google Scholar
Man-Son-Hing M, Laupacis A. 2003 Anticoagulant-related bleeding in older persons with atrial fibrillation: Physicians' fears often unfounded. Arch Intern Med. 163: 15801586.Google Scholar
McCall KL, MacLaughlin EJ. 2003 Ximelagatran: A new era in oral anticoagulation. J Pharm Technol. 19: 222228.Google Scholar
Raskob GE, Hull RD, Pineo GF. 2001: Venous thrombosis. In: Beutler E, Coller BS, Lichtman MA, Kipps TJ, eds. Williams hematology. 6th ed. New York: McGraw-Hill; 17351741.
Schulman S, Wåhlander K, Lundström T, et al. 2003 Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 349: 17131721.Google Scholar
Stringer KA, Lopez LM. Uncomplicated myocardial infarction. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. 1999: Pharmacotherapy: a pathophysiologic approach. 5th ed. New York: McGraw-Hill; 251271.
Wallentin L, Wilcox RG, Weaver WD, et al. 2003 Oral ximelagatran for secondary prophylaxis after myocardial infarction: The ESTEEM randomised controlled trial. Lancet. 362: 789797.Google Scholar
Weitz J. 2003 Orally active direct thrombin inhibitors. Semin Vasc Med. 3: 131137.Google Scholar